Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Oct 14 - Oct 19
We next extended this finding to persistent chemical injury models beyond DSS colitis
For CDMOs, contract testing laboratories and other outsourced manufacturers, the implications are particularly significant the FDA considers contractors extensions of the manufacturer, meaning AI governance gaps at a contract facility can directly translate into compliance risk for the sponsor
ATTAIN-1 (orforglipron, 72 weeks): Discontinuation due to AEs: 5.3-10.3% (orforglipron) vs 2.7% placebo Key characteristics: GI profile is broadly similar to injectable GLP-1 agonists despite oral route Nausea rates are comparable to tirzepatide The oral formulation does not appear to worsen GI tolerability relative to SC injection Safety profile described as "consistent with injectable GLP-1 medicines" Ecnoglutide# Ecnoglutide is a cAMP-biased GLP-1 receptor agonist developed by Sciwind Biosciences
Mice were administered a single topical drop (2.5 L) of NAC (18.35 mg/mL) or NACET (21.5 mg/mL) gel-forming drops, or gel-forming vehicle alone bilaterally daily starting from when their eyes opened (P13-15) through P65
I do not use other forms of reduced glutathione, as they have poor absorption and do not generally make it through the digestive system intact
